Brazil steps closer to reagents self-reliance
This article was originally published in Clinica
Brazilian efforts to develop low-cost diagnostic reagents took a major step forward yesterday, with the approval of further funding for the R$106m (US$55m) centre that will house the country's largest production facility. The national development bank (BNDES) has committed R$30m to building the "integrated centre for prototypes, biopharmaceuticals and reagents" (CIPBR), which is scheduled to come into operation in 2009, as part of the Fiocruz foundation's Biomanguinhos biologics R&D division.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.